T. A. Yap, . Aerts, . Jg, S. Popat, . Fennell et al., Novel insights into mesothelioma biology and implications for therapy, Nat Rev Cancer, vol.17, pp.475-488, 2017.

M. J. Atherton, L. Evgin, . Keller, . Ba, . Shenouda et al., , 2017.

, Infectious Optimism following the 10th International Oncolytic Virus Meeting, Mol Ther Oncolytics, vol.7, pp.12-16

D. Haddad, Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery, Front Oncol, p.96, 2017.

B. W. Robinson, . Mukherjee, . Sa, A. Davidson, S. Morey et al., Cytokine gene therapy or infusion as treatment for solid human cancer, J Immunother, vol.21, pp.211-217, 1998.

S. Mukherjee, T. Haenel, R. Himbeck, B. Scott, I. Ramshaw et al., , 2000.

, Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation, Cancer Gene Ther, vol.7, pp.663-670

K. J. Kelly, Y. Woo, P. Brader, Z. Yu, C. Riedl et al., Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma, Hum Gene Ther, vol.19, pp.774-782, 2008.

P. Brader, . Kelly, . Kj, N. Chen, Y. A. Yu et al., Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene, Clin Cancer Res, vol.15, pp.3791-3801, 2009.

L. J. Belin, . Ady, . Jw, C. Lewis, D. Marano et al., An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma, Surgery, vol.154, pp.486-495, 2013.

U. M. Lauer, M. Schell, J. Beil, S. Berchtold, U. Koppenhofer et al., Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis, Clin Cancer Res, vol.24, pp.4388-4398, 2018.

J. Foloppe, J. Kempf, N. Futin, J. Kintz, P. Cordier et al., The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism, Mol Ther Oncolytics, vol.14, pp.1-14, 2019.

Y. Aye, M. Li, M. J. Long, . Weiss, and . Rs, Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies, Oncogene, vol.34, pp.2011-2021, 2015.

C. Achard, N. Boisgerault, T. Delaunay, D. Roulois, S. Nedellec et al., Sensitivity of pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response, Oncotarget Dec, vol.29, pp.44892-44904, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01285131

Z. Waibler, M. Anzaghe, T. Frenz, A. Schwantes, C. Pohlmann et al., , 2009.

, Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components, J Virol, vol.83, pp.1563-1571

Z. Liu, R. Ravindranathan, J. Li, P. Kalinski, Z. S. Guo et al., CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy, Oncoimmunology, vol.5, p.1091554, 2016.

E. K. Moon, . Wang, . Ls, K. Bekdache, . Lynn et al., Intratumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines, Oncoimmunology, vol.7, p.1395997, 2018.

S. A. Acuna, K. Ottolino-perry, B. Cako, N. Tang, F. A. Angarita et al., , 2014.

, Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma, Annals of surgical oncology, vol.21, pp.2259-2266

L. Fend, T. Yamazaki, C. Remy, C. Fahrner, M. Gantzer et al., Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-alpha Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy, Cancer Res, vol.77, pp.4146-4157, 2017.

B. Heinrich, J. Klein, M. Delic, K. Goepfert, V. Engel et al., Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes, OncoTargets and therapy, vol.10, pp.2389-2401, 2017.